Search research articles
Contact Us
Filters
Showing results (361-370 of 578) with videos related to
Page
of 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2008
In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement
Patrick Neven, Olivier Brouckaert, Vanya Van Belle, et al.
Gynecologic Oncology
|
December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer
Ignace Vergote, Florian Heitz, Paul Buderath, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 14, 2007
ESGO statement on cervical cancer vaccination
Ignace Vergote, Ate G J van der Zee, Vesna Kesic, et al.
Cancers
|
April 3, 2021
Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients
Thomas Bartl, Jasmine Karacs, Caroline Kreuzinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2010
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, et al.
Medical Oncology (Northwood, London, England)
|
June 27, 2014
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
Jalid Sehouli, Klaus Pietzner, Pauline Wimberger, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 5, 2026
Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial
Kan Yonemori, Shin Nishio, Shiro Suzuki, et al.
Breast Cancer Research and Treatment
|
October 25, 2006
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging
Leilani Morales, Steven Pans, Robert Paridaens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Neoplasia (New York, N.Y.)
|
February 22, 2018
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer
Mandy Stanske, Stephan Wienert, Dan Cacsire Castillo-Tong, et al.
Page
of 58
Search research articles
Search
Showing results (361-370 of 578) with videos related to
Sort By:
Page
of 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2008
In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement
Patrick Neven, Olivier Brouckaert, Vanya Van Belle, et al.
Gynecologic Oncology
|
December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer
Ignace Vergote, Florian Heitz, Paul Buderath, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 14, 2007
ESGO statement on cervical cancer vaccination
Ignace Vergote, Ate G J van der Zee, Vesna Kesic, et al.
Cancers
|
April 3, 2021
Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients
Thomas Bartl, Jasmine Karacs, Caroline Kreuzinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2010
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, et al.
Medical Oncology (Northwood, London, England)
|
June 27, 2014
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
Jalid Sehouli, Klaus Pietzner, Pauline Wimberger, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 5, 2026
Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial
Kan Yonemori, Shin Nishio, Shiro Suzuki, et al.
Breast Cancer Research and Treatment
|
October 25, 2006
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging
Leilani Morales, Steven Pans, Robert Paridaens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Neoplasia (New York, N.Y.)
|
February 22, 2018
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer
Mandy Stanske, Stephan Wienert, Dan Cacsire Castillo-Tong, et al.
Page
of 58